Companies › FBD Biologics
2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HCB301 Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein | SIRPA, PDCD1LG2, TGFB1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| HCB101 SIRPα-Fc fusion protein targeting CD47 | SIRPA, CD47 | Phase 1 | Advanced Solid Tumor; Solid Cancer; CRC; HNSCC | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07204574 | HCB101 | Phase 1 | CRC | Oncology | Dec 2025 |
| NCT06487624 | HCB301 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07136545 | HCB101 | Phase 1 | HNSCC | Oncology | Dec 2026 |
| NCT05892718 | HCB101 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT06771622 | HCB101 | Phase 1 | Solid Cancer | Oncology | Jan 2028 |
Pfizer Bristol-Myers Squibb Phanes Therapeutics Sairopa Electra Therapeutics Kahr Medical Byondis Biotheus Boehringer Ingelheim GSK
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.